American Society of Hirudotherapy

The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia

Narrative review published in Seminars in thrombosis and hemostasis (2004)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentGreinacher · Seminars in thrombosis and hemostasis, 2004

Abstract

One of the most important adverse drug reactions that physicians encounter is the life- and limb-threatening prothrombotic syndrome known as heparin-induced thrombocytopenia (HIT). Unfractionated heparin (UFH), administered during cardiopulmonary bypass (CPB), is highly immunogenic. Heparin-dependent antibodies can develop in 25 to 50% of UFH-treated cardiac surgery patients within 5 to 10 days. These antibodies can activate platelets and are considered the causative agents of HIT. HIT is a relatively common complication, occurring in 1 to 3% of cardiovascular surgery patients when UFH administration is continued postoperatively. It is strongly associated with new thromboembolic events leading to limb amputation and death. In acute or recent (< 100 days) HIT, alternative anticoagulatory regimens are needed during CPB surgery for prevention of HIT-related thrombosis. Treatment options for such patients now generally include the use of alternative anticoagulants such as lepirudin, bivalirudin, or danaparoid, as well as a combined treatment with platelet-function inhibitors and heparin. In patients with a history of HIT and no detectable antibodies, heparin is currently the safest approach for high-dose anticoagulation during CPB. Before and after surgery, however, alternative anticoagulants should be used. The risk of clinical HIT after heart surgery could potentially be reduced by using low-molecular-weight heparins for postsurgery anticoagulation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiovascular DiseasesClinical Trials as TopicEnzyme-Linked Immunosorbent AssayHeparinHirudinsHumansPlatelet CountRecombinant ProteinsThrombinThrombocytopeniaTime Factors

Summary

Review of anticoagulation strategies for cardiopulmonary bypass and postoperative care in heparin-induced thrombocytopenia: patients with acute or recent HIT need alternatives such as lepirudin, bivalirudin or danaparoid, while antibody-negative patients with past HIT can receive heparin intraoperatively.

Why This Matters for Hirudotherapy

This review examines the management of heparin-induced thrombocytopenia (HIT) in cardiovascular surgery, where HIT occurs in 1–3% of patients receiving postoperative unfractionated heparin and is strongly associated with new thromboembolic events leading to limb amputation and death. The article discusses lepirudin (recombinant hirudin) alongside bivalirudin and danaparoid as alternative anticoagulants for patients requiring cardiopulmonary bypass who have acute or recent HIT, and recommends heparin for patients with a history of HIT but no detectable antibodies. The review positions lepirudin — a direct leech-derived anticoagulant — as an important therapeutic option in a high-risk surgical population. The review presents no original data, and lepirudin is one of several alternatives discussed.

Citation

Reference (Vancouver style)

Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 2004;30(3):315-327. doi:10.1055/s-2004-831044. PMID: 15282654

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.